Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announced the presentation of data highlighting the performance of its Solus Gold Embolization Device during a session on new embolization devices at the 2021 Global Embolization Symposium and Technologies (GEST) annual meeting on July 31st, 2021.
PRAIRIE VILLAGE, Kan., Aug. 10, 2021 /PRNewswire/ -- Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announced the presentation of data highlighting the performance of its Solus Gold Embolization Device during a session on new embolization devices at the 2021 Global Embolization Symposium and Technologies (GEST) annual meeting on July 31st, 2021. Data from a good laboratory practice (GLP) study comparing the performance of Artio’s Solus Gold Embolization Device with Medtronic’s MVP™ Micro Vascular Plug System in a nonclinical model was presented by Dr. Blaise Baxter, a peripheral vascular and neurovascular and interventional radiologist at the Lehigh Valley Health Network in Allentown, Pennsylvania. The Solus Gold and MVP devices were sized per recommendation and used to treat seven study subjects with up to five devices per subject, randomized to left or right sided treatments via femoral or carotid artery access. The average time to complete angiographic occlusion for the Solus Gold device was 6 seconds, compared to 9.5 minutes for MVP. Additionally, 100% of Solus Gold implants maintained complete occlusion 90 days after placement, compared to 40% of the MVP devices. None of the Solus Gold implants migrated from the treatment site during the study period, compared to 40% migration of the MVP devices, and no compression of either device was seen. “I was pleased with the results of this study and encouraged by the potential of the Solus Gold device to overcome the limitations of current devices by providing precision placement, shorter occlusion times, higher rates of complete vessel occlusion over time, and less device migration.” commented Dr. Baxter. For those with online access to GEST, the on-demand presentation can be viewed at: https://gest2021.gestweb.org/program/program/106/oral-abstracts-pre-clinical-new-devices-lab-sciences. About Artio Medical About the Solus Gold ™ Embolization Device Data from this GLP study can be found on file at Artio Medical, Inc. View original content to download multimedia:https://www.prnewswire.com/news-releases/artio-medicals-solus-gold-embolization-device-featured-at-2021-gest-conference-301351835.html SOURCE Artio Medical, Inc. |